Lv5
900 积分 2022-05-31 加入
ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications
28天前
已完结
FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis
5个月前
已完结
FOLR1-stabilized β-catenin promotes laryngeal carcinoma progression through EGFR/AKT/GSK-3β pathway
5个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
11个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
1年前
已完结
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
1年前
已完结
皖公网安备34019202002308
